Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Characterization of Immune Response to Intradermal Influenza Vaccination
NCT06067555Phase 1Completed
- Sponsor
- Yale University
- Start
- Jan 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) in influenza (3 arms), sponsored by Yale University. Primary endpoints: Change in antibody titer concentration to vaccination-Blood at Day 28 and Change in antibody titer concentration to vaccination-Skin at Day 28. Started Jan 2024; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06067555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067555.